Table 3. Prescription Drug Misuse: Lifetime Exposure Among IDUs Recruited in New York, Los Angeles, and New Orleans Between 2004 and 2006 (N=213).
| Drug Class | Brand Name | Generic Name | DEA Schedule | Total Sample
(N=213) |
NSDUH
(2004) |
|---|---|---|---|---|---|
| Opioids
(Pain Relievers) |
Vicodin | Hydrocodone | II | 84.0% | 16.5% |
| Methylmorphine * | Codeine | II,III,V | 75.1% | 6.4% | |
| Oxycontin | Oxycodone | II | 69.0% | 4.3% | |
| Percocet | Oxycodone | II | 66.2% | 8.7%† | |
| MS Contin * | Morphine | II | 65.3% | 2.5% | |
| Dolophine * | Methadone | II | 54.9% | 1.4% | |
| Demerol | Meperidine | II | 52.6% | 1.9% | |
| Dilaudid | Hydromorphone | II | 51.2% | .3% | |
| Percodan | Oxycodone | II | 40.4% | 8.7%† | |
| Alfentanil * | Fentanyl | II | 30.0% | NA | |
| Darvon | Propoxyphene | II, IV | 28.6% | 13.1% | |
| Benzodiazepines
(Tranquilizers) |
Xanax | Alprazolam | IV | 79.8% | 7.7%‡ |
| Valium | Diazapam | IV | 78.9% | 7.6% | |
| Klonopin | Clonazepam | IV | 73.7% | 3.3% | |
| Ativan | Lorazepam | IV | 31.5% | 7.7%‡ | |
| Librium | Chlodiazepoxide | IV | 16.7% | NA | |
| Halcion | Triazolam | IV | 2.3% | .2% | |
| Stimulants | Ritalin | Methylphenidate | II | 53.5% | 5.4% |
| Adderall | Dextroamphetamine | II | 40.4% | .3% | |
| Desoxyn | Methamphetamine | II | 6.1% | 5.2% | |
| Barbiturates
(Sedatives) |
Phenobarb * | Phenobarbital | IV | 28.2% | .3% |
| Seconal | Secobarbital | II | 10.3% | .4%§ | |
| Nembutal | Pentobarbital | II | 6.1% | .4%§ | |
| Amytal | Amobarbital | II | 5.2% | .1% | |
| Sedative | Quaalude | Methaqualone | I | 23.5% | .8% |
†
asked about Percocet, Percodan, or Tylox in same question
‡
asked about Xanax or Ativan in same question
§
asked about Nembutal, Seconal, or butalbital in same question.
*
More commonly known generic names were asked during interview.